Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00377481




Registration number
NCT00377481
Ethics application status
Date submitted
15/09/2006
Date registered
18/09/2006
Date last updated
2/11/2016

Titles & IDs
Public title
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
Scientific title
A Randomised, Cross-Over Study to Investigate the Comfort of Injection of Renal Anaemia Patients Receiving Subcutaneous NeoRecormon® Compared to Darbepoetin Alfa.
Secondary ID [1] 0 0
ML20339
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anemia 0 0
Condition category
Condition code
Blood 0 0 0 0
Anaemia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - darbepoetin alfa
Treatment: Drugs - epoetin beta [NeoRecormon]

Experimental: 1 -

Active Comparator: 2 -


Treatment: Drugs: darbepoetin alfa
30 micrograms sc weekly (2 doses)

Treatment: Drugs: epoetin beta [NeoRecormon]
6000 IU sc weekly (2 doses)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Local pain due to s.c. injection (by VAS).
Timepoint [1] 0 0
After each injection
Secondary outcome [1] 0 0
Patient preference.
Timepoint [1] 0 0
At end of study
Secondary outcome [2] 0 0
AEs, vital signs.
Timepoint [2] 0 0
Throughout study

Eligibility
Key inclusion criteria
- adult patients, >18 years of age;

- patients with renal anemia or post-transplant anemia.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- poorly controlled hypertension;

- known hypersensitivity to NeoRecormon or darbepoetin alfa.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Crossover
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/06/2007
Sample size
Target
Accrual to date
Final
48
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Adelaide
Recruitment hospital [2] 0 0
- Gosford
Recruitment hospital [3] 0 0
- Liverpool
Recruitment hospital [4] 0 0
- Melbourne
Recruitment hospital [5] 0 0
- Parkville
Recruitment hospital [6] 0 0
- St. Leonards
Recruitment hospital [7] 0 0
- Sydney
Recruitment hospital [8] 0 0
- Woolloongabba
Recruitment postcode(s) [1] 0 0
5011 - Adelaide
Recruitment postcode(s) [2] 0 0
2250 - Gosford
Recruitment postcode(s) [3] 0 0
2170 - Liverpool
Recruitment postcode(s) [4] 0 0
3168 - Melbourne
Recruitment postcode(s) [5] 0 0
3052 - Parkville
Recruitment postcode(s) [6] 0 0
2065 - St. Leonards
Recruitment postcode(s) [7] 0 0
NSW 2148 - Sydney
Recruitment postcode(s) [8] 0 0
4102 - Woolloongabba

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will assess the comfort of subcutaneous injections of NeoRecormon and darbepoetin
alfa (Aranesp) in patients with renal anemia. Eligible patients will be randomized to receive
comparable subcutaneous injections of either darbepoetin alfa (30 micrograms) or NeoRecormon
(6000IU). They will then be crossed over to the alternative treatment arm for further
treatment. After each injection pain will be assessed using the visual analogue scale (VAS)
and 6-point verbal rating scale (VRS), and patient preference will be assessed. The
anticipated time on study treatment is <3 months, and the target sample size is <100
individuals.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00377481
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00377481